Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FENC NASDAQ:INBX NASDAQ:PDSB NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$8.78-2.9%$7.83$3.96▼$9.30$242.33M0.3992,884 shs109,351 shsINBXInhibrx Biosciences$21.77+3.8%$14.27$10.80▼$22.31$315.14M-0.0497,840 shs62,977 shsPDSBPDS Biotechnology$1.24-4.6%$1.46$0.85▼$4.42$56.68M1.21471,078 shs442,161 shsVORVor Biopharma$2.50+8.2%$0.64$0.13▼$3.29$312.40M2.044.76 million shs15.99 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies-2.88%+1.09%+7.07%+75.25%+46.33%INBXInhibrx Biosciences+3.77%+33.68%+48.30%+87.51%+67.85%PDSBPDS Biotechnology-4.62%-7.19%-29.14%+20.39%-64.77%VORVor Biopharma+8.23%+32.63%+1,036.36%+257.14%+164.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFENCAdherex Technologies2.2528 of 5 stars3.61.00.00.02.03.30.0INBXInhibrx Biosciences2.5645 of 5 stars0.03.00.04.62.22.51.3PDSBPDS Biotechnology1.3055 of 5 stars3.71.00.00.01.70.00.0VORVor Biopharma3.9055 of 5 stars4.35.00.00.02.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFENCAdherex Technologies 3.25Buy$13.0048.06% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/APDSBPDS Biotechnology 3.33Buy$9.00625.81% UpsideVORVor Biopharma 2.60Moderate Buy$5.63125.14% UpsideCurrent Analyst Ratings BreakdownLatest PDSB, FENC, VOR, and INBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/30/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.006/26/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Outperform6/11/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.005/20/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/15/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/14/2025FENCAdherex TechnologiesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.005/9/2025VORVor BiopharmaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025VORVor BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform$6.00 ➝ $6.005/9/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/8/2025VORVor BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFENCAdherex Technologies$47.54M5.10$0.03 per share271.86($0.21) per share-41.81INBXInhibrx Biosciences$200K1,576.15$114.58 per share0.19$9.23 per share2.36PDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/AVORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFENCAdherex Technologies-$440K-$0.51N/AN/AN/A-45.52%N/A-26.37%8/12/2025 (Estimated)INBXInhibrx Biosciences$1.69B$116.750.19N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)PDSBPDS Biotechnology-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/12/2025 (Estimated)VORVor BiopharmaN/A-$1.51N/AN/AN/AN/AN/AN/AN/ALatest PDSB, FENC, VOR, and INBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q4 2024INBXInhibrx Biosciences-$2.55-$2.80-$0.25-$2.80N/AN/A5/14/2025Q1 2025PDSBPDS Biotechnology-$0.25-$0.21+$0.04-$0.21N/AN/A5/13/2025Q1 2025FENCAdherex Technologies-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFENCAdherex TechnologiesN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFENCAdherex TechnologiesN/A5.134.97INBXInhibrx Biosciences1.045.125.12PDSBPDS Biotechnology0.292.332.33VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFENCAdherex Technologies55.51%INBXInhibrx Biosciences82.46%PDSBPDS Biotechnology26.84%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipFENCAdherex Technologies11.76%INBXInhibrx Biosciences17.09%PDSBPDS Biotechnology9.20%VORVor Biopharma2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFENCAdherex Technologies1027.60 million24.35 millionOptionableINBXInhibrx Biosciences16614.48 million12.00 millionOptionablePDSBPDS Biotechnology2045.71 million41.51 millionOptionableVORVor Biopharma140124.96 million65.45 millionNot OptionablePDSB, FENC, VOR, and INBX HeadlinesRecent News About These CompaniesVor Biopharma Names Sandy Mahatme Chief Financial OfficerJuly 11 at 5:37 AM | marketwatch.comVor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business OfficerJuly 11 at 5:37 AM | finanznachrichten.deVor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business OfficerJuly 10 at 4:00 PM | globenewswire.comVor Biopharma Sees Unusually Large Options Volume (NYSE:VOR)July 10 at 2:38 AM | americanbankingnews.comVor Biopharma: Not So Sure About This Surge, And Do Mind The WarrantsJuly 8, 2025 | seekingalpha.comBiopharma layoffs for first half of the year jump 32% YOYJuly 8, 2025 | fiercebiotech.comFVor Biopharma Target of Unusually High Options Trading (NYSE:VOR)July 8, 2025 | marketbeat.comAnalysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $5.63July 8, 2025 | americanbankingnews.comBoston’s biotech sector reels due to Trump health policy uncertaintyJuly 6, 2025 | ft.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 5, 2025 | marketbeat.comHC Wainwright Predicts Weaker Earnings for Vor BiopharmaJuly 4, 2025 | americanbankingnews.comVor Biopharma Q2 EPS Estimate Decreased by HC WainwrightJuly 2, 2025 | marketbeat.comHC Wainwright Upgrades Vor Biopharma (NYSE:VOR) to "Buy"July 2, 2025 | americanbankingnews.comVor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comHC Wainwright & Co. Upgrades Vor Biopharma (VOR)June 30, 2025 | msn.comVor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune MarketJune 30, 2025 | benzinga.comVor Bio Stock Skyrockets 250% in the Past Week: Here's WhyJune 30, 2025 | zacks.comVor Biopharma (NYSE:VOR) Upgraded at HC WainwrightJune 30, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Gains Momentum S&P 500June 27, 2025 | kalkinemedia.comKVor Biopharma Inc. Stock Grades - Barron'sJune 27, 2025 | barrons.comVor Biopharma (NYSE:VOR) Stock Price Expected to Rise, Robert W. Baird Analyst SaysJune 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonWhich Analyst-Favorite Drone Stock Will Come Out on Top?By Nathan Reiff | June 25, 2025View Which Analyst-Favorite Drone Stock Will Come Out on Top?More Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for OutperformanceTop Steel Picks for the Coming Infrastructure BoomBy Chris Markoch | June 25, 2025View Top Steel Picks for the Coming Infrastructure BoomSizzling Insider Buys for Your High-Yield WatchlistBy Thomas Hughes | July 8, 2025View Sizzling Insider Buys for Your High-Yield WatchlistPDSB, FENC, VOR, and INBX Company DescriptionsAdherex Technologies NASDAQ:FENC$8.78 -0.26 (-2.88%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$8.76 -0.01 (-0.17%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Inhibrx Biosciences NASDAQ:INBX$21.77 +0.79 (+3.77%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$21.74 -0.02 (-0.11%) As of 07/11/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.PDS Biotechnology NASDAQ:PDSB$1.24 -0.06 (-4.62%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.25 +0.01 (+0.40%) As of 07/11/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Vor Biopharma NYSE:VOR$2.50 +0.19 (+8.23%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.57 +0.07 (+2.80%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
